Sitemap > News > Metabolic & Hormonal Disorders
Displaying 1 - 50 of 1052 results
- Indevus Reports Positive Data From Phase III NEBIDO Trial
- Surface Logix Starts Phase 2A Clinical Trial of SLx-4090 in Dyslipidemia
- Schering-Plough and Bayer Healthcare Announce Availability of ZETIA in Japan, the First Cholesterol-Lowering Agent With a Novel Mechanism of Action Approved in Japan in 18 Years
- Phase III clinical trial with 4-month long-acting formulation of triptorelin: Ipsen decides not to perform further administration
- Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
- DEPOMED INITIATES DOSING OF PATIENTS IN PHASE 2 TRIAL FOR GABAPENTIN GR FOR THE TREATMENT OF MENOPAUSAL HOT FLASHES
- FDA Advisory Committee did not recommend approval of rimonabant (Zimulti®) for use in obese and overweight patients with associated risks factors
- LCT successfully transplants first diabetes patient
- Keryx Biopharmaceuticals Announces Completion of Patient Randomization Into Sulonex Phase III Pivotal Study
- Surface Logix Starts Phase 2A Clinical Trial of SLx-4090 in Dyslipidemia
- Metabasis Therapeutics Announces Initiation of a Clinical Trial for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia
- Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
- VIVUS Completes End of Phase 2 Meeting with the FDA for Qnexa, a Treatment for Obesity
- New data from multiple studies show Galvus® delivers consistent and robust blood sugar control in patients with type 2 diabetes
- Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
- Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
- Shire Demonstrates Commitment To Improving Patient Adherence In End Stage Renal Disease As New Phosphate-Binder FOSRENOL® Launches In Europe
- Late Breaking Data Released at ADA Showed that the Investigational Use of JANUVIA™ (sitagliptin) and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
- BYETTA® Study Showed Comparable Blood Glucose Control to Insulin
- BYETTA® Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
- Amlodipine and Olmesartan Study Results Released
- SYMLIN(R) Used in Conjunction with Basal Insulin in Patients with Type 2 Diabetes
- Orexigen™ Therapeutics Reports Contrave™ Has Positive Effect on Visceral Fat and Insulin Resistance, Factors Believed to Contribute to the Risk of Heart Disease and Type II Diabetes
- BENTLEY REPORTS POSITIVE RESULTS WITH NASULIN INTRANASAL INSULIN SPRAY AT THE AMERICAN DIABETES ASSOCIATION MEETING
- Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
- First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
- DiObex Presents Phase 2a Data of DIO-902
- Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
- Exubera Demonstrated Pulmonary Safety with Blood Sugar Control in Three-Year Interim Analyses
- For any given level of HbA1c, Lantus demonstrates less confirmed hypoglycemia over Insulin NPH
- Apidra Improved A1C In People With Type 2 Diabetes When Added to Basal Insulin And Oral Antidiabetic Treatments (BOT)
- Obecure Completes Treatment of Patients in Phase II Obesity Trial
- Generex Biotechnology to Initiate Phase III Clinical Trial of Generex Oral-lyn in 2007 Third Quarter
- CYTOCHROMA REPORTS POSITIVE PHASE I CLINICAL DATA FOR CTA018 INJECTION
- SPEEDEL REPORTS SUCCESSFUL SPP635 PHASE IIA TRIAL IN HYPERTENSION
- Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
- Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target
- Positive Trial Results - Combination Contraceptive Sprays
- GTx Initiates Phase IIb Ostarine Clinical Trial for Cancer Cachexia
- TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
- CORCEPT THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FOR CORLUX® TREATMENT OF CUSHING’S SYNDROME
- LifeCycle Pharma to Initiate Phase II Clinical Trial of LCP-AtorFen for the Treatment of High Cholesterol Levels
- Tranzyme Receives FDA Fast Track Designation for TZP-101
- Hollis-Eden Pharmaceuticals Reports Initial Results in Phase I Clinical Trial of HE3286 as New Type II Diabetes Treatment
- Metabasis Therapeutics Announces CS-917 Phase 2b Clinical Trial Results and Reports on Status of Pradefovir
- Metabolex Announces Full Enrollment of Phase 2/3 Study of MBX-102/JNJ 39659100 in Patients with Type 2 Diabetes
- Aclasta recommended for European approval as the first once-yearly treatment for women with postmenopausal osteoporosis
- Tercica Completes Enrollment of Clinical Trial MS301 Evaluating Treatment with Increlex in Children with Primary IGFD
- Wyeth Receives Approvable Letter From FDA for PRISTIQ for the Treatment of Vasomotor Symptoms Associated With Menopause
- Athersys Begins Phase I Trial for ATHX-105 for Treatment of Obesity